Home > Insider Trading > Filing (0001127602-22-011550)

Filing Details

Accession Number:: 0001127602-22-011550
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-04-05 16:17:39
Reporting Period:: 2022-03-17

Accepted Time:: 2022-04-05 16:17:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1145197	Insulet Corp	PODD	Surgical & Medical Instruments & Apparatus (3841)	043523891

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1631895	Shacey Petrovic	C/O Insulet Corporation 100 Nagog Park Acton MA 01720	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-03-17	19,903	$0.00	13,607	No	5	G	Direct
Common Stock	Acquisiton	2022-03-17	19,903	$0.00	26,304	No	5	G	Indirect	By SP Trust
Common Stock	Acquisiton	2022-04-04	15,000	$29.26	28,607	No	4	M	Direct
Common Stock	Disposition	2022-04-04	15,000	$273.25	13,607	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Direct
No	5	G	Indirect	By SP Trust
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2022-04-04	15,000	$0.00	15,000	$29.26

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,070		2026-02-24	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	61,259	Indirect	By NG Trust

Footnotes

On March 17, 2022, the reporting person transferred 19,903 shares of Insulet common stock to a family trust of which the reporting person is a trustee. The reporting person and members of her immediate family are beneficiaries of the trust.
The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $270.79 to $279.59. Specifically: 4,146 shares were sold in the range of $270.79 to $271.77 per share, with a weighted average share price of $271.35; 1,928 shares were sold in the range of $271.79 to $272.73 per share, with a weighted average share price of $272.10; 3,111 shares were sold in the range of $272.80 to $273.77 per share, with a weighted average share price of $273.30; 3,618 shares were sold in the range of $273.78 to $274.77 per share, with a weighted average share price of $274.21; 1,413 shares were sold in the range of $274.78 to $275.35 per share, with a weighted average share price of $275.08; 200 shares were sold in the range of $276.09 to $276.37 per share, with a weighted average share price of $276.23; 142 shares were sold in the range of $277.64 to $278.39 per share, with a weighted average share price of $278.20 and 442 shares were sold in the range of $278.66 to $279.59 per share, with a weighted average share price of $279.28. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.